Cara Therapeutics (CARA) Stock Rating Reaffirmed by Stifel Nicolaus

Cara Therapeutics (NASDAQ:CARA)‘s stock had its “buy” rating reiterated by equities researchers at Stifel Nicolaus in a research report issued to clients and investors on Wednesday. They presently have a $17.00 target price on the biopharmaceutical company’s stock. Stifel Nicolaus’ price target would indicate a potential upside of 33.12% from the company’s current price.

CARA has been the topic of a number of other reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Cara Therapeutics in a research note on Wednesday, October 4th. Scotiabank upped their price objective on shares of Cara Therapeutics from $31.00 to $31.50 and gave the company an “outperform” rating in a research note on Tuesday, October 17th. Raymond James Financial increased their target price on shares of Cara Therapeutics from $25.00 to $26.00 and gave the stock a “market perform” rating in a research note on Tuesday, November 7th. Canaccord Genuity set a $25.00 target price on shares of Cara Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 20th. Finally, ValuEngine lowered shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $24.97.

Cara Therapeutics (NASDAQ CARA) traded down $0.75 during mid-day trading on Wednesday, reaching $12.77. 1,397,500 shares of the company were exchanged, compared to its average volume of 1,456,933. The firm has a market cap of $418.37, a PE ratio of -5.58 and a beta of 2.96. Cara Therapeutics has a twelve month low of $10.09 and a twelve month high of $28.50.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.03). During the same period last year, the business posted ($0.42) EPS. equities research analysts anticipate that Cara Therapeutics will post -1.84 EPS for the current fiscal year.

In other Cara Therapeutics news, CEO Derek T. Chalmers sold 16,000 shares of Cara Therapeutics stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $12.66, for a total transaction of $202,560.00. Following the transaction, the chief executive officer now directly owns 1,066,292 shares of the company’s stock, valued at $13,499,256.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 7.70% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in shares of Cara Therapeutics by 17.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,107,874 shares of the biopharmaceutical company’s stock valued at $17,050,000 after buying an additional 164,247 shares in the last quarter. Gotham Asset Management LLC purchased a new position in shares of Cara Therapeutics in the 2nd quarter worth about $448,000. C WorldWide Group Holding A S raised its position in shares of Cara Therapeutics by 76.6% in the 3rd quarter. C WorldWide Group Holding A S now owns 291,341 shares of the biopharmaceutical company’s stock worth $3,988,000 after purchasing an additional 126,330 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Cara Therapeutics in the 3rd quarter worth about $451,000. Finally, Swiss National Bank purchased a new position in shares of Cara Therapeutics in the 2nd quarter worth about $651,000. Institutional investors and hedge funds own 58.64% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3127050/cara-therapeutics-cara-stock-rating-reaffirmed-by-stifel-nicolaus.html.

About Cara Therapeutics

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.